{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Neuroendocrine+Carcinoma&page=5",
    "query": {
      "condition": "Advanced Neuroendocrine Carcinoma",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 450,
    "total_pages": 45,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Neuroendocrine+Carcinoma&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Neuroendocrine+Carcinoma&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T02:40:10.234Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02498665",
      "title": "A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndromes",
        "Glioblastoma Multiforme",
        "Melanoma",
        "Non-Small Cell Lung Cancer",
        "Ovarian Cancer",
        "Pancreatic Cancer",
        "Sarcoma",
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "DSP-7888 Dosing Emulsion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2015-11",
      "completion_date": "2018-09",
      "has_results": false,
      "last_update_posted_date": "2023-11-14",
      "last_synced_at": "2026-10-10T02:40:10.234Z",
      "location_count": 8,
      "location_summary": "Denver, Colorado • Atlanta, Georgia • Lafayette, Indiana + 5 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Lafayette",
          "state": "Indiana"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02498665"
    },
    {
      "nct_id": "NCT04047251",
      "title": "A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Merkel Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "FF-10850 Topotecan Liposome Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fujifilm Pharmaceuticals U.S.A., Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2019-11-14",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-10-10T02:40:10.234Z",
      "location_count": 7,
      "location_summary": "Scottsdale, Arizona • Denver, Colorado • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04047251"
    },
    {
      "nct_id": "NCT05824975",
      "title": "A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Metastatic Solid Tumor",
        "Soft Tissue Sarcoma (STS)",
        "Platinum-resistant Ovarian Cancer (PROC)",
        "Hepatocellular Carcinoma (HCC)",
        "Colorectal Cancer (CRC)",
        "HER2 Negative Breast Cancer",
        "Cutaneous Melanoma",
        "Renal Cell Carcinoma (RCC)"
      ],
      "interventions": [
        {
          "name": "GI-102 subcutaneous (SC)",
          "type": "DRUG"
        },
        {
          "name": "GI-102",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "eribulin",
          "type": "DRUG"
        },
        {
          "name": "trastuzumab deruxtecan (T-DXd)",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GI Innovation, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 358,
      "start_date": "2023-05-30",
      "completion_date": "2027-04-24",
      "has_results": false,
      "last_update_posted_date": "2024-11-25",
      "last_synced_at": "2026-10-10T02:40:10.234Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05824975"
    },
    {
      "nct_id": "NCT03241173",
      "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignancies"
      ],
      "interventions": [
        {
          "name": "INCAGN01949",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Biosciences International Sàrl",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2017-10-09",
      "completion_date": "2019-09-17",
      "has_results": true,
      "last_update_posted_date": "2022-09-27",
      "last_synced_at": "2026-10-10T02:40:10.234Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03241173"
    },
    {
      "nct_id": "NCT04348916",
      "title": "Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer",
        "Melanoma",
        "Solid Tumor",
        "Squamous Cell Carcinoma of Head and Neck",
        "Breast Cancer",
        "Advanced Solid Tumor",
        "Triple Negative Breast Cancer",
        "Colorectal Carcinoma",
        "Non-melanoma Skin Cancer",
        "Liver Metastases"
      ],
      "interventions": [
        {
          "name": "ONCR-177",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Oncorus, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2020-05-20",
      "completion_date": "2023-05-31",
      "has_results": false,
      "last_update_posted_date": "2023-06-08",
      "last_synced_at": "2026-10-10T02:40:10.234Z",
      "location_count": 10,
      "location_summary": "Duarte, California • Denver, Colorado • Tampa, Florida + 6 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04348916"
    },
    {
      "nct_id": "NCT03435640",
      "title": "REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Merkel Cell Carcinoma",
        "Triple Negative Breast Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Renal Cell Carcinoma",
        "Colorectal Cancer",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "NKTR-262",
          "type": "DRUG"
        },
        {
          "name": "bempegaldesleukin",
          "type": "DRUG"
        },
        {
          "name": "nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nektar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2018-03-15",
      "completion_date": "2022-05-09",
      "has_results": true,
      "last_update_posted_date": "2023-03-08",
      "last_synced_at": "2026-10-10T02:40:10.234Z",
      "location_count": 14,
      "location_summary": "Scottsdale, Arizona • La Jolla, California • Tampa, Florida + 11 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03435640"
    },
    {
      "nct_id": "NCT01782443",
      "title": "Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoid Tumor"
      ],
      "interventions": [
        {
          "name": "Ziv-aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2013-02-13",
      "completion_date": "2021-12-26",
      "has_results": true,
      "last_update_posted_date": "2023-08-14",
      "last_synced_at": "2026-10-10T02:40:10.234Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01782443"
    },
    {
      "nct_id": "NCT02646748",
      "title": "Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Cancer (CRC)",
        "Endometrial Cancer",
        "Melanoma",
        "Head and Neck Cancer",
        "Lung Cancer",
        "MMR-deficient Tumors",
        "Breast Cancer",
        "Pancreatic Cancer",
        "Renal Cell Carcinoma (RCC)",
        "Solid Tumors",
        "UC (Urothelial Cancer)"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "itacitinib",
          "type": "DRUG"
        },
        {
          "name": "INCB050465",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 159,
      "start_date": "2016-01-25",
      "completion_date": "2020-11-20",
      "has_results": false,
      "last_update_posted_date": "2022-03-31",
      "last_synced_at": "2026-10-10T02:40:10.234Z",
      "location_count": 17,
      "location_summary": "San Francisco, California • Santa Monica, California • Washington D.C., District of Columbia + 12 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02646748"
    },
    {
      "nct_id": "NCT00004074",
      "title": "Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Adult Primary Liver Cancer",
        "Anaplastic Thyroid Cancer",
        "Bone Metastases",
        "Carcinoma of the Appendix",
        "Distal Urethral Cancer",
        "Fallopian Tube Cancer",
        "Gastrinoma",
        "Glucagonoma",
        "Inflammatory Breast Cancer",
        "Insulinoma",
        "Liver Metastases",
        "Localized Unresectable Adult Primary Liver Cancer",
        "Lung Metastases",
        "Male Breast Cancer",
        "Malignant Pericardial Effusion",
        "Malignant Pleural Effusion",
        "Metastatic Gastrointestinal Carcinoid Tumor",
        "Metastatic Parathyroid Cancer",
        "Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter",
        "Newly Diagnosed Carcinoma of Unknown Primary",
        "Occult Non-small Cell Lung Cancer",
        "Pancreatic Polypeptide Tumor",
        "Primary Peritoneal Cavity Cancer",
        "Proximal Urethral Cancer",
        "Pulmonary Carcinoid Tumor",
        "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity",
        "Recurrent Adrenocortical Carcinoma",
        "Recurrent Adult Primary Liver Cancer",
        "Recurrent Anal Cancer",
        "Recurrent Bladder Cancer",
        "Recurrent Breast Cancer",
        "Recurrent Carcinoma of Unknown Primary",
        "Recurrent Cervical Cancer",
        "Recurrent Colon Cancer",
        "Recurrent Endometrial Carcinoma",
        "Recurrent Esophageal Cancer",
        "Recurrent Extrahepatic Bile Duct Cancer",
        "Recurrent Gallbladder Cancer",
        "Recurrent Gastric Cancer",
        "Recurrent Gastrointestinal Carcinoid Tumor",
        "Recurrent Islet Cell Carcinoma",
        "Recurrent Malignant Testicular Germ Cell Tumor",
        "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity",
        "Recurrent Non-small Cell Lung Cancer",
        "Recurrent Ovarian Epithelial Cancer",
        "Recurrent Pancreatic Cancer",
        "Recurrent Parathyroid Cancer",
        "Recurrent Prostate Cancer",
        "Recurrent Rectal Cancer",
        "Recurrent Renal Cell Cancer",
        "Recurrent Salivary Gland Cancer",
        "Recurrent Small Intestine Cancer",
        "Recurrent Squamous Cell Carcinoma of the Larynx",
        "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Recurrent Squamous Cell Carcinoma of the Nasopharynx",
        "Recurrent Squamous Cell Carcinoma of the Oropharynx",
        "Recurrent Thyroid Cancer",
        "Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter",
        "Recurrent Urethral Cancer",
        "Recurrent Vaginal Cancer",
        "Recurrent Vulvar Cancer",
        "Skin Metastases",
        "Small Intestine Adenocarcinoma",
        "Somatostatinoma",
        "Stage III Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage III Adrenocortical Carcinoma",
        "Stage III Bladder Cancer",
        "Stage III Cervical Cancer",
        "Stage III Colon Cancer",
        "Stage III Endometrial Carcinoma",
        "Stage III Esophageal Cancer",
        "Stage III Follicular Thyroid Cancer",
        "Stage III Gastric Cancer",
        "Stage III Malignant Testicular Germ Cell Tumor",
        "Stage III Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage III Ovarian Epithelial Cancer",
        "Stage III Pancreatic Cancer",
        "Stage III Papillary Thyroid Cancer",
        "Stage III Prostate Cancer",
        "Stage III Rectal Cancer",
        "Stage III Renal Cell Cancer",
        "Stage III Salivary Gland Cancer",
        "Stage III Squamous Cell Carcinoma of the Larynx",
        "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage III Squamous Cell Carcinoma of the Nasopharynx",
        "Stage III Squamous Cell Carcinoma of the Oropharynx",
        "Stage III Vaginal Cancer",
        "Stage III Vulvar Cancer",
        "Stage IIIA Anal Cancer",
        "Stage IIIA Breast Cancer",
        "Stage IIIA Non-small Cell Lung Cancer",
        "Stage IIIB Anal Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIB Non-small Cell Lung Cancer",
        "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage IV Adrenocortical Carcinoma",
        "Stage IV Anal Cancer",
        "Stage IV Bladder Cancer",
        "Stage IV Breast Cancer",
        "Stage IV Colon Cancer",
        "Stage IV Endometrial Carcinoma",
        "Stage IV Esophageal Cancer",
        "Stage IV Follicular Thyroid Cancer",
        "Stage IV Gastric Cancer",
        "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage IV Non-small Cell Lung Cancer",
        "Stage IV Ovarian Epithelial Cancer",
        "Stage IV Pancreatic Cancer",
        "Stage IV Papillary Thyroid Cancer",
        "Stage IV Prostate Cancer",
        "Stage IV Rectal Cancer",
        "Stage IV Renal Cell Cancer",
        "Stage IV Salivary Gland Cancer",
        "Stage IV Squamous Cell Carcinoma of the Larynx",
        "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IV Squamous Cell Carcinoma of the Nasopharynx",
        "Stage IV Squamous Cell Carcinoma of the Oropharynx",
        "Stage IVA Cervical Cancer",
        "Stage IVA Vaginal Cancer",
        "Stage IVB Cervical Cancer",
        "Stage IVB Vaginal Cancer",
        "Stage IVB Vulvar Cancer",
        "Thyroid Gland Medullary Carcinoma",
        "Unresectable Extrahepatic Bile Duct Cancer",
        "Unresectable Gallbladder Cancer",
        "Urethral Cancer Associated With Invasive Bladder Cancer",
        "WDHA Syndrome"
      ],
      "interventions": [
        {
          "name": "recombinant interleukin-12",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ABI-007/carboplatin/trastuzumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "1999-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-28",
      "last_synced_at": "2026-10-10T02:40:10.234Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004074"
    },
    {
      "nct_id": "NCT01262235",
      "title": "A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cancer",
        "Neuroendocrine Tumors",
        "NET",
        "Adrenocortical Carcinoma",
        "ACC"
      ],
      "interventions": [
        {
          "name": "TKM-080301",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arbutus Biopharma Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2010-12",
      "completion_date": "2015-08",
      "has_results": false,
      "last_update_posted_date": "2019-01-16",
      "last_synced_at": "2026-10-10T02:40:10.234Z",
      "location_count": 8,
      "location_summary": "Scottsdale, Arizona • Tampa, Florida • Iowa City, Iowa + 4 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01262235"
    }
  ]
}